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Abstract
Background: Insurance companies use medical information to classify the mortality risk of applicants. Adding genetic tests
to this assessment is currently being debated. This debate would be more meaningful, if results of present-day risk
prediction were known. Therefore, we compared the predicted with the observed mortality of men who applied for life
insurance, and determined the prognostic value of the risk assessment.
Methods: Long-term follow-up was available for 62,334 male applicants whose mortality risk was predicted with medical
evaluation and they were assigned to five groups with increasing risk from 1 to 5. We calculated all cause standardized
mortality ratios relative to the Dutch population and compared groups with Cox’s regression. We compared the
discriminative ability of risk assessments as indicated by a concordance index (c).
Results: In 844,815 person years we observed 3,433 deaths. The standardized mortality relative to the Dutch male
population was 0.76 (95 percent confidence interval, 0.73 to 0.78). The standardized mortality ratios ranged from 0.54 in risk
group 1 to 2.37 in group 5. A large number of risk factors and diseases were significantly associated with increased
mortality. The algorithm of prediction was significantly, but only slightly better than summation of the number of disorders
and risk factors (c-index, 0.64 versus 0.60, P,0.001).
Conclusions: Men applying for insurance clearly had better survival relative to the general population. Readily available
medical evaluation enabled accurate prediction of the mortality risk of large groups, but the deceased men could not have
been identified with the applied prediction method.
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Introduction
Insurance companies classify applicants according to their
mortality risk. The applicant’s risk is estimated from the history of
disease and the presence of risk factors. Mortality tables of a
reference population and algorithms for assessment of risk are
based on medical literature (population-based studies, publications
of the natural history of diseases, and intervention trials) and
public databases [1,2]. However, it is likely that policy-holders are
healthier than patients in medical studies, and in general insurance
contracts last much longer than follow-up in medical studies.
Moreover, it is impossible to anticipate effects of novel medical
interventions during the lifetime of the contract. Assessment of
multiple (and competing) risk factors may improve the estimation
of the individual risk, and proposals to include genetic information
are currently being debated [2–6]. Molecular diagnostics may
enhance the individual risk assessment and may lead to
personalized medicine in the case of treatable disorders.
Therefore, it may be expected that genetic testing in the future
will improve the accuracy of the underwriting. But major concerns
exists that genetic testing leads to discrimination and, therefore,
governments have restricted the use of genetic information by
insurers [7].
A fundamental principle of life insurance is to guarantee
compensation for loss of income or liability in respect to an event
that cannot be predicted with certainty. The risk of an individual is
allocated to large numbers of people. Improving the discriminative
ability of predicting mortality risk may, from this point of view, be
undesirable. Whether present-day underwriting has any prognos-
tic value is unknown and this complicates the discussion about
improving the risk assessment. For example, the discussion about
adding (genetic) tests related to common diseases may prove to be
a purely theoretical exercise in case applicants have low absolute
mortality risks. It is unlikely that a better prediction method
(higher likelihood) will have any relevance in populations with very
low risk. Even within families, the mortality from untreated
monogenic disorders shows large variation, which reduces the
value of molecular diagnostics for the underwriting process [8].
Probably, the burden of a few very rare Mendelian disorders can
be well predicted by molecular means, but family history offers
the insurer an opportunity to identify health risks and to set, if
necessary, specific premiums without extra costs of tests.
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5457
We hypothesized that the present-day underwriting has no
relevant discriminative ability and improving this risk assessment
with additional tests will be difficult, because the majority of
applicants is characterized by low risk. Therefore, we compared a
simple risk assessment method in male applicants for life insurance
related to mortgage, widows’ pensions, or income with the
observed mortality during long-term follow-up. In addition, we
assessed the prognostic value of the risk prediction.
Methods
Ethics statement
The study was approved by the Medical Ethics Committee of
the Erasmus MC and all applicants gave written informed consent
for risk analyses and actuarial studies.
Subjects
Medical records were available of 62,378 applicants whose
mortality risk was estimated because they applied for life insurance
(mortgage insurance, widows’ pensions, and income protection).
The intake of the applicants was performed between June 1, 1962
and June 1, 1990. In 2002, we ended the follow-up. We excluded
44 men because of incompleteness of information resulting in a
study population of 62,334 men. The data were initially stored on
punch cards, and a number of electronic databases were used
thereafter. The databases were merged and anonymized for the
present study.
Risk assessment
The medical officers performed risk classifications by calculating
the mortality ratio relative to reference populations using age,
duration of the contract, history of common diseases, and the
presence of risk factors [1,2]. All applicants completed a health
questionnaire. Weight and length were measured and a body mass
index was calculated. Unfortunately, only obesity was documented
in the database: obesity was tagged when the body mass index was
above 30 kg/m2. Medical examination was performed when the
medical officer required additional medical information on
indication and when the average insured amount was equal to
or above $45,000, which gradually increased during 28 calendar
years up to $65,000. Serum glucose and urinary tests for glucose
and albumin were included; HIV-testing was added in 1987.
Screening of serum total and high-density lipoprotein cholesterol
levels was added in 1990. In Table 1, only the most frequent
disorders (above 0.5 percent) are shown, though the full medical
history of each applicant was obtained.
Individual mortality risk was predicted by summation of risk
factor specific percentages according to guidelines that were made
by the actuarial and medical departments of Nationale-Nederlan-
den. The risk factor specific percentages in these guidelines were
based on life expectancies in long term clinical studies and life
tables of the general population [1,2,8–10]. During the years, the
risk factor specific percentages were adjusted according to changes
in mortality of the reference population and/or changes in life
expectancy resulting from new medical treatments. The most
important changes were based on adjustments for diabetes
mellitus, hypertension, and survival after coronary artery bypass
grafting [11–18]. The risk of each client was estimated and
expressed as percentage. After summation of the excess mortalities
related to risk factors and diseases the medical officer assigned the
client to one of five risk groups: applicants without overt risk
factors were assigned to group 1 (100 percent); applicants with an
estimated risk 101–130 percent to group 2; 131–200 percent to
group 3; 201–400 percent to group 4; and above 400 percent to
group 5. Tables of risk factor and disease specific death rates were
provided in guidelines made by the actuarial and medical
departments of Nationale-Nederlanden. The expected deaths
were estimated by the actuary with age and male specific annual
death rates of the Dutch Central Bureau of Statistics (CBS). The
total expected deaths of persons with age x(0) obtaining insurance
at t = 0 for the duration of n years is estimated with
Etotal~
Xn
t~1
t{1 px 0ð Þ:qx 0ð Þzt{1

in which px(0) is the probability that (x) will live one year and qx(0) is
the probability that (x) will die within n year(s). The death rates
observed by CBS were used as qx(0). The year starts at t21 and
ends at t. We need to consider the survival probabilities (px(0)),
because during long follow-up and/or in case of disorders with
large excess mortality the px(0) becomes substantially smaller than
1. For example a male client of 58 years with epilepsy, who applied
for life insurance in 1965, had an annual death rate of 10% in the
CBS statistics. The client had a 49% death rate during 7 years
(and not 7.10= 70%). Relative to group 1, a mortality risk of
232% was estimated assigning the client to group 4.
Statistical analyses
All cause mortality was compared with the mortality in the male
Dutch population standardized for age and calendar period as
described previously [8,19]. Briefly, the standardized mortality
ratio is the ratio of observed to expected number of deaths. We
calculated the expected mortality by multiplying the total number
of years lived by the men in each calendar period for each age
category by the age and male specific mortality rates of the Dutch
population for each calendar period. We compared mortality
between subgroups with Cox’s regression (relative risk). Cumula-
tive survival was analyzed with the Kaplan-Meier method. We
censored participants when they died or reached the end of the
insurance contract (on December 31, 2002 the last contracts
ended). We calculated the 95 percent confidence interval of the
standardized mortality ratio assuming a Poisson distribution of the
observed number of deaths and using exact limits. We calculated
the 95 percent confidence interval of the relative risk with Cox’s
regression as the exponent of the regression coefficient and its
standard error. Significance was assessed at the 5 percent level of
probability.
The discriminative ability of predictive models was evaluated by
comparing the concordance indices (c) using S-plus for Windows
2000 [20]. The concordance statistic for survival data indicates the
probability that for a randomly chosen pair of persons, the one
having the higher predicted survival is the one who survives
longer: 0.5 indicates no discriminative ability and 1.0 indicates no
false classifications. An internal validation was performed by
taking 100 random bootstrap samples [21].
Results
We have analyzed data on 62,334 males with a mean follow-up
of 13 (SD69) years (median 12; range 4 months to 41 years). The
medical evaluation was performed at a mean age of 37 (SD610;
median 36) years ranging from 18 to 77. Table 1 shows the most
frequent baseline medical findings.
During follow-up, a total of 3,433 deaths were observed in
844,815 person years. The all cause mortality relative to the Dutch
male population standardized for age and calendar period was
0.76 (95 percent confidence interval, 0.73 to 0.78, P,0.001).
Risk Prediction by Insurer
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The standardized mortality ratio according to predicted risk is
shown in Table 2. Risk groups 1 and 2 had a better life expectancy
than the Dutch population. The mortality risk of group 3 was
similar to that of the Dutch population. Significant excess
mortality relative to the Dutch population was observed in risk
groups 4 and 5. The standardized mortality ratio of group 5 was
2.37 (95 percent confidence interval, 2.04 to 2.75, P,0.001). We
also performed direct comparisons using risk group 1 as a
reference group in a Cox’s model with adjustment for year of birth
and age at medical evaluation. Group 2 had 1.34 (95 percent
confidence interval, 1.23 to 1.46), group 3 had 1.87 (95 percent
confidence interval, 1.69 to 2.07), group 4 had 3.03 (95 percent
confidence interval, 2.68 to 3.43), and group 5 had 4.64 (95
percent confidence, 3.90 to 5.53) times increased mortality risk
relative to group 1 (all P,0.001). Figure 1 shows the difference in
cumulative survival between the risk groups (Log-rank test
P,0.001).
The associations between specific baseline findings and
mortality during follow-up were determined with Cox’s regression
adjusted for the year of birth and age at medical evaluation
(Table 1). Coronary artery disease (angina pectoris, myocardial
infarction, and coronary by-pass grafting), other cardiovascular
disorders (atrial fibrillation, heart failure, peripheral vascular
disease, cardiomyopathy, subarachnoid hemorrhage, cerebrovas-
cular accident, valve disease, and congenital disorders), a positive
family history of cardiovascular disease, elevated blood pressure
Table 1. The most frequent findings in a Dutch male cohort and the association with mortality within this cohort.
Risk Factor n Percentage (95% CI) Relative risk (95% CI) P-value
Cardiovascular risk factors
Angina pectoris, myocardial infarction, CABG 1034 1.7 (1.6–1.8) 2.23 (1.90–2.62) ,0.001
Other cardiovascular disorders 2927 4.7 (4.5–4.9) 1.20 (1.04–1.38) 0.01
Family history of cardiovascular disease 3116 5.0 (4.8–5.2) 1.20 (1.01–1.42) 0.04
Blood pressure above 145/90 mmHg* 8414 13.5 (13.2–13.8) 1.55 (1.43–1.69) ,0.001
Hypertension{ 1691 2.7 (2.6–2.8) 1.66 (1.36–2.04) ,0.001
History of cholesterol above 5.5 mmol/L 1246 2.0 (1.9–2.1) 1.14 (0.87–1.49) 0.4
Diabetes mellitus (onset before age 30) 429 0.7 (0.6–0.8) 3.27 (2.32–4.62) ,0.001
Diabetes mellitus (onset on or after age 30) 647 1.0 (0.96–1.1) 2.08 (1.61–2.53) ,0.001
Body mass index above 30 kg/m2 1471 2.4 (2.2–2.5) 1.04 (0.73–1.49) 0.8
Smoking of more than 20 cigarettes daily 5081 8.2 (7.9–8.4) 1.54 (1.39–1.72) ,0.001
Other risk factors
Alcohol consumption above 60 g daily 2019 3.2 (3.1–3.4) 1.38 (1.17–1.61) ,0.001
Chronic obstructive pulmonary disease 2378 3.8 (3.7–4.0) 1.55 (1.29–1.85) ,0.001
Psychiatric disorder 6548 10.5 (10.3–10.7) 1.13 (1.01–1.27) 0.04
Epilepsy 816 1.3 (1.2–1.4) 2.14 (1.62–2.84) ,0.001
Malignancies 798 1.3 (1.2–1.4) 1.78 (1.39–2.29) ,0.001
Low back pain 2201 3.5 (3.4–3.7) 0.54 (0.35–0.83) 0.005
Osteoarthritis, rheumatic disorders 490 0.8 (0.7–0.9) 1.72 (1.27–2.33) ,0.001
Herniated vertebral disc 1325 2.1 (2.0–2.2) 0.95 (0.75–1.21) 0.7
Cox’s regression analysis was performed with adjustment for year of birth and age at medical evaluation.
CABG denotes coronary artery by-pass grafting; CI denotes confidence interval; other cardiovascular disorders were atrial fibrillation, heart failure, peripheral vascular
disease, cardiomyopathy, subarachnoid hemorraghe, cerebrovascular accident, valve disease, and congenital disorder.
*measurement of blood pressure performed by the general practitioner or the medical officer during a single office visit.
{hypertension was diagnosed by general practitioner or specialist and treatment with antihypertensive medication was started.
doi:10.1371/journal.pone.0005457.t001
Table 2. Mortality in a large male cohort compared to the Dutch population according to a priori risk classification.
Risk group No of men Person years No of deaths Standardized mortality ratio (95% confidence interval)
1 24,666 358,296 942 0.54 (0.50 to 0.57)
2 22,137 302,857 1,185 0.70 (0.66 to 0.74)
3 11,164 138,841 739 0.96 (0.89 to 1.03)
4 3,469 36,728 389 1.57 (1.41 to 1.73)
5 898 8,092 178 2.37 (2.04 to 2.75)
Total group 62,334 844,815 3,433 0.76 (0,73 to 0.78)
doi:10.1371/journal.pone.0005457.t002
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during a single office visit, hypertension, diabetes mellitus, smoking
more than 20 cigarettes daily, consuming more than 60 g alcohol
daily, chronic obstructive pulmonary disease, psychiatric disorders,
epilepsy, malignancies, osteoarthritis and rheumatic disorders were
all significantly associated with an increased mortality risk. Obesity
was found in 2.4 percent (95 percent confidence interval, 2.2 to 2.4
percent) of the applicants and was not associated with excess
mortality. Those with obesity had significantly more often
hypertension (4.9 versus 2.7 percent, p,0.001) and tended to
have more often type 2 diabetes (2.0% versus 1.0%, p= 0.09)
compared to non-obese clients. The serum total cholesterol
concentration was not routinely measured during the medical
evaluation and the information about hypercholesterolemia was
only available in a minority of the client’s histories. In this
subgroup, hypercholesterolemia was not associated with an
increased mortality risk. Low back pain and herniated vertebral
disc did not contribute to mortality. In fact, low back pain was
associated with a low relative mortality risk (0.54, 95 percent
confidence interval, 0.35–0.83). Obese persons had more often low
back pain than non-obese (5.3 versus 3.5 percent, p,0.001). In
886 person years, we did not observe deaths among 78 obese
persons with low back pain while the expected standardized rate
was 3 (expected number of deaths).
The risk of one up to the combination of three disorders relative
to the group without baseline disorders increased in a dose
dependent manner: 1.45 up to 2.39 (see Table 3).
In all Cox’s regression analyses, the year of birth had a
significant inverse relation with mortality (relative risk 0.97, 95
percent confidence interval, 0.96 to 0.98). Age was positively
associated with mortality (relative risk 1.06, 95 percent confidence
interval, 1.05 to 1.07).
We have estimated c-indices to evaluate the accuracy of the
following risk prediction methods: the individual risk predictions
and the classification in 5 risk groups had virtually identical c-
indices (0.64, 95 percent confidence interval, 0.63 to 0.65). The
actuarial risk predictions were significantly more accurate than
simple counting of disorders and risk factors (P,0.001). The c-
index of just counting the number of disorders was 0.60 (95
percent confidence interval, 0.59 to 0.61).
Discussion
We have analyzed a large male cohort with long-term follow-up
and we have found that the classification of the men according to
mortality risk correlated with the observed mortality. Insurance
companies often request medical information and our results
Figure 1. Survival during follow-up in a large male cohort according to a priori risk prediction. The Kaplan-Meier curves show a
significant association between predicted risk and observed life expectancy.
doi:10.1371/journal.pone.0005457.g001
Table 3. The observed mortality relative to combinations of disorders and risk factors that were documented at baseline.
Number of Disorders and/or Risk Factors n Percentage (95% CI*) Relative risk (95% CI*) P-value
subjects without finding 9,594 15.4 (15.1–15.7) 1.00
subjects with one finding 35,150 56.4 (56.0–56.8) 1.45 (1.29–1.62) ,0.001
subjects with two findings 13,594 21.8 (21.5–22.1) 1.76 (1.56–1.98) ,0.001
subjects with three findings 3,996 6.4 (6.2–6.6) 2.39 (2.08–2.75) ,0.001
Cox’s regression analysis was performed with adjustment for year of birth and age at medical evaluation.
*CI denotes confidence interval.
doi:10.1371/journal.pone.0005457.t003
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suggest that relatively simple information can be used to make
accurate risk assessments of groups. The risk predictions are needed
to substantiate risk specific premiums and to avoid acceptance at
standard risk of persons with very short life expectancy. Nonethe-
less, the deceased men in our cohort could not have been identified
individually by the limited medical evaluation.
In general, severely ill and disabled persons do not apply for
insurance. Hence, as expected, we observed selection of healthy
individuals. Although the cohort had a better life expectancy
compared to the general Dutch population, we were able to
observe a large variation of mortality and clear excess mortality in
risk groups 4 and 5. Cardiovascular diseases and cardiovascular
risk factors, especially diabetes mellitus, strongly contributed to
variation of mortality risk. Neurologic disorders, malignancies,
disorders with arthritis, and chronic obstructive pulmonary disease
were also associated with an increased risk of death. Although the
present population had a better overall life expectancy, the
mortality risk estimates of the disorders and risk factors were in
accordance with those in population-based studies [8–10]. As
expected, low back pain did not contribute to mortality and was
even associated with improved prognosis! To our knowledge, this
is the first report of an inverse association between low back pain
and mortality. It is tempting to hypothesize that low back pain
leads to risk avoidance [22].
Our results support that simple risk assessment is accurate to set
the price of the premium for groups of applicants and suggests that
additional tests result in extra costs without clear benefits. The low
absolute risk of the majority of applicants suggests that additional
(for instance, genetic) tests would need to provide a level of
prediction higher than currently achievable to improve the
individual risk prediction.
Risk prediction is necessary to estimate the costs of insurances
and to calculate optimal premiums. The final premium will be
influenced by market demands and competition among insurance
companies as well as medical and ethical issues determining the
choice between risk specific premiums and generalizable risk
assignment. Although an insurance company may not be
interested in (investing in) medical information from applicants,
it may still need to consider other factors as a result of clients’
demands. Non-smokers may refuse to pay for smokers’ risk. Thin
clients may not want to pay for the risk of obesity. Clients may ask
for reduced premiums as a reward for a healthy lifestyle and a
favourable genotype. Such public demands for predictive power of
medical evaluations may result in highly risk-dependent insurance
premiums. Prediction of individual risk may be improved by
adding multiple risk factors such as levels of apolipoproteins A1
and B, lipoprotein(a), high-density lipoprotein cholesterol, homo-
cysteine, tumour markers, and genetic information [2,23,24].
However, in a low risk population, the extra costs of these tests are
solely intended to avoid selection of adverse risk.
Obviously the strength of the present study lies in the long-term
prospective follow-up of a relatively healthy population and the
availability of excellent general population statistics enabling
reliable analyses of all cause mortality: prospective follow-up of
long lasting insurance contracts resulted in a unique historical
cohort and enabled assessment of the absolute risk. Our study
offers a basis for discussions about improving risk prediction by
insurers and whether or not additional tests are useful [25]. A
weakness is the lack of complete information on a number of risk
factors because their importance was not yet apparent in 1962. For
example, we had blood pressure measurements from only a single
office visit, whereas the seventh Joint National Committee (JNC 7)
proposed a definition of hypertension based on the average of two
or more visits [26]. Nevertheless, we found that increased blood
pressure during a single office visit was clearly associated with
excess mortality, confirming findings of others [27]. Remarkably,
treated hypertension was still associated with excess mortality. This
may be explained by a late diagnosis, lack of compliance, or
insufficient treatment. We found severe excess mortality among
clients with type 1 and insulin dependent type 2 diabetes. During
more recent years, the prognosis of patients with type 1 diabetes
may have improved considerably [28]. Moreover, Japanese
patients had greater excess mortality than Finnish patients with
type 1 diabetes [29]. Hence, our estimates may not apply to the
present-day male patient with diabetes mellitus and may not be
generalized to populations in other countries. Obesity was not
associated with excess mortality, but we lack insight in the exact
contrast between the obese and non-obese group. Body mass
indexes were not available in the database, because only obesity
(body mass index equal to or above 30 kg/m2) was tagged in the
database. Although obesity was rare and only available as
dichotomous variable in our historical cohort, obese persons had
more often hypertension and tended to a higher frequency of type
2 diabetes. A limited number of applicants had information about
previous cholesterol measurements and, in an even smaller group,
total cholesterol was measured during the medical evaluation.
Hypercholesterolemia was not associated with increased mortality
reflecting the lack of sufficient information.
We conclude that medical evaluation by an insurance company
enables accurate prediction of the mortality risk of large groups of
men. Cardiovascular and neurologic diseases, malignancies,
arthritis, and chronic obstructive pulmonary disease were
associated with an increased mortality risk. However, decedents
could not have been identified individually by the medical
evaluation employed. The low mortality risk of our population
suggests that individual risk prediction is unlikely to achieve
relevant post-test probabilities, which is in support of equal
opportunities for those who are seeking life insurance.
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